
Conference Coverage
about 8 hours ago
IMS 2026: Beth Faiman Talks New Definition of Myeloma Cure and MoreLatest Content

FDA Approves Maintenance Tucatinib for Advanced HER2+ Breast Cancer

National PA Week: Mark Honor on the Growth of APPs in Oncology Care

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

IMS 2026: Beth Faiman Talks New Definition of Myeloma Cure and More

WCLC 2026: Katherine Kuhns Details AI, Wearables & Perioperative Care Roles

Shorts










Videos
All News

Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.

Five-week hypofractionated radiation after prostatectomy showed similar 5-year cancer control and quality of life but more grade 3 urinary toxicity.

Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.

Dr. Wendy Harpham reflects on her journey as a physician and patient, emphasizing precise clinical communication in oncology care.

FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.

Most oral blood cancer drug prescriptions were first rejected by insurers, and fill rates fell sharply when out-of-pocket costs topped $175.

At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.

At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.

At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.

ASTRO 2026 presenter Kayla Kafka-Peterson details an Adapt-Adopt-Build model to bridge global brachytherapy nursing gaps and standardize perioperative care.

Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinic workflows, safety checks, and at-home dosing potential for on-body isatuximab.

Solid tumor history, cardiopulmonary symptom burden, and age-dependent chemo intensity predicted 30-day readmission or death after AML induction.

At ASTRO 2026, Dr. Nitin Ohri details additive versus synergistic toxicities when combining radiation with novel systemic therapies in clinical trials.

APHON 2026 speaker Amy C. Haskamp, CNS, discusses tiered self-care tactics and boundaries to help pediatric oncology nurses navigate emotional distress and burnout.

For Gynecologic Cancer Awareness Month, Amy Schultz, RN, details symptom identification, barrier mitigation, and caregiver support in oncology care.
















































































